Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil

Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil

Alternative title Análise de custo-efetividade de análogos da somatostatina no tratamento de acromegalia no Brasil
Author Valentim, Joice Google Scholar
Passos, Vanessa Google Scholar
Mataveli, Fabio Autor UNIFESP Google Scholar
Calabró, Alessandra Google Scholar
Institution Universidade de São Paulo (USP)
Novartis Pharmaceuticals
Universidade Federal de São Paulo (UNIFESP)
Novartis Biociências S.A.
Abstract This study aims to compare economic and patient impacts of the treatment of acromegaly with two different somatostatin analogues (octreotide LAR and lanreotide SR) in Brazil. A cost-effectiveness analysis was carried out under the Brazilian Public Health Care System (SUS) perspective. A decision analytical model was developed based on the Brazilian Public Health Care System Clinical Guideline for Acromegaly. A hypothetical cohort of 276 patients was followed for two years. Data were extracted from literature and administrative databases. Based on the analytical model, treatment with octreotide LAR would avoid 12 and 17 cases of GH and IGF-I elevated serum levels, respectively. Octreotide LAR was a cost-saving strategy, with net savings of R$10,448,324 (US$4,465,096) to SUS. Annual net savings per patient were R$ 18,928 (US$8,089). Treatment of acromegaly with octreotide LAR is a dominant strategy when compared to the treatment with lanreotide SR in Brazil. Sensitivity analysis did not alter the cost-saving status.

O objetivo deste estudo é comparar o impacto econômico e o impacto nos pacientes com acromegalia do tratamento com dois diferentes análogos de somatostatina (octreotida LAR e lanreotide SR) no Brasil. Um estudo de custoefetividade foi realizado a partir da perspectiva do Sistema Único de Saúde (SUS). Foi desenvolvido um modelo analítico de decisão baseado no Protocolo Clínico e Diretrizes Terapêuticas de Acromegalia do SUS. Uma coorte hipotética de 276 pacientes foi seguida por dois anos. Dados foram obtidos da literatura e bases de dados oficiais do SUS. Baseado no modelo analítico, o tratamento com octreotida LAR evitaria 12 e 17 casos com níveis elevados de GH e IGF-I, respectivamente. Octreotida LAR foi uma estratégia econômica, gerando economia de R$10.448.324 (US$4.465.096) para o SUS. A economia anual por paciente foi de R$18.928 (US$8.089). O tratamento de acromegalia com octreotida LAR é estratégia dominante quando comparado com o tratamento com lanreotida SR no Brasil. A análise de sensibilidade não alterou seu status de econômica.
Keywords Cost effectiveness
Acromegaly
Somatostatin analogues
Octreotide
Lanreotide
Custo-efetividade
Acromegalia
Análogo de somatostatina
Octreotida
Lanreotida
Language English
Date 2008-12-01
Published in Arquivos Brasileiros de Endocrinologia & Metabologia. Sociedade Brasileira de Endocrinologia e Metabologia, v. 52, n. 9, p. 1452-1460, 2008.
ISSN 0004-2730 (Sherpa/Romeo, impact factor)
Publisher Sociedade Brasileira de Endocrinologia e Metabologia
Extent 1452-1460
Origin http://dx.doi.org/10.1590/S0004-27302008000900008
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000262399800008
SciELO ID S0004-27302008000900008 (statistics in SciELO)
URI http://repositorio.unifesp.br/handle/11600/4737

Show full item record




File

Name: S0004-27302008000900008.pdf
Size: 131.0Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account